Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Recurrent or Metastatic Breast Cancer”

220 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 220 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07179939
What this trial is testing

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Who this might be right for
HER2-positive Breast Cancer
Fudan University 288
Testing effectiveness (Phase 2)Ended earlyNCT00470249
What this trial is testing

Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
University of Southampton 5
Testing effectiveness (Phase 2)Ended earlyNCT01912963
What this trial is testing

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 32
Large-scale testing (Phase 3)Looking for participantsNCT06103864
What this trial is testing

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 625
Post-approval studies (Phase 4)Not Yet RecruitingNCT07357597
What this trial is testing

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.

Who this might be right for
Stomatitis
AstraZeneca 100
Testing effectiveness (Phase 2)Looking for participantsNCT06682793
What this trial is testing

Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Who this might be right for
Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more
A2 Biotherapeutics Inc. 240
Large-scale testing (Phase 3)Looking for participantsNCT07533123
What this trial is testing

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

Who this might be right for
Triple Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 364
Early research (Phase 1)Study completedNCT02833155
What this trial is testing

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Taizhou EOC Pharma Co., Ltd. 19
Early research (Phase 1)Study completedNCT01816035
What this trial is testing

Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

Who this might be right for
HER2/Neu PositiveRecurrent Breast CarcinomaStage IIIB Breast Cancer+2 more
University of Washington 13
Testing effectiveness (Phase 2)Study completedNCT03328026
What this trial is testing

Combination Study of SV-BR-1-GM With Retifanlimab

Who this might be right for
Breast CancerBreast NeoplasmMetastatic Breast Cancer+1 more
BriaCell Therapeutics Corporation 36
Testing effectiveness (Phase 2)Study completedNCT00699491
What this trial is testing

Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Who this might be right for
Male Breast CarcinomaRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
National Cancer Institute (NCI) 48
Testing effectiveness (Phase 2)Ended earlyNCT00824733
What this trial is testing

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Bhuvaneswari Ramaswamy 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT05445908
What this trial is testing

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer and HR+/HER2- BC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 175
Large-scale testing (Phase 3)Study completedNCT03371017
What this trial is testing

The Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer

Who this might be right for
Triple Negative Breast Neoplasms
Hoffmann-La Roche 595
Testing effectiveness (Phase 2)Ended earlyNCT00096109
What this trial is testing

Tanespimycin in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Recurrent Breast CancerStage IIIB Breast CancerStage IIIC Breast Cancer+1 more
National Cancer Institute (NCI) 11
Testing effectiveness (Phase 2)Study completedNCT01269346
What this trial is testing

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Eisai Inc. 52
Testing effectiveness (Phase 2)Study completedNCT00258375
What this trial is testing

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
NCIC Clinical Trials Group 15
Testing effectiveness (Phase 2)Ended earlyNCT03795012
What this trial is testing

Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
MedSIR 22
Post-approval studies (Phase 4)Study completedNCT02445586
What this trial is testing

Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 52
Testing effectiveness (Phase 2)Study completedNCT01268150
What this trial is testing

Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Who this might be right for
Locally RecurrentMetastatic Breast Cancer ( HER2 Negative)
Eisai Inc. 56
Load More Results